Condition
Siewert Type III Adenocarcinoma of Esophagogastric Junction
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown2
Not Yet Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07441785Recruiting
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
NCT06277921Completed
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
NCT06277908Not Yet Recruiting
Postoperative Morbidity and Mortality After Gastric Cancer Surgery
NCT04151524Unknown
Classification of Adenocarcinoma of the Esophagogastric Junction
NCT02313688Not ApplicableUnknown
Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
Showing all 5 trials